The latest from CDMOs, CMOs, and suppliers featuring Bora Pharmaceuticals, Emergent, and Fujifilm Diosynth Biotechnologies.  

Biologics Manufacturing 
* Fujifilm Diosynth Opens Microbial Biomanufacturing Facility 
Formulation Development/Drug Product Manufacturing 
* Bora Pharmaceuticals Completes Acquisition of Sterile Mfg Facility from Emergent 

---

Biologics Manufacturing 

Fujifilm Diosynth Opens Microbial Biomanufacturing Facility 
Fujifilm Diosynth Biotechnologies has opened a new £100-million ($131-million).microbial fermentation manufacturing facility in Billingham, UK. The new facility triples existing microbial production throughput with the addition of a new production line equipped with 2 X 4,000-L fermenters, a primary separations suite, and a modular purification suite.  

Source: Fujifilm Diosynth Biotechnologies 

---

Formulation Development/Drug Product Manufacturing 

Bora Pharmaceuticals Completes Acquisition of Sterile Mfg Facility from Emergent   
Bora Pharmaceuticals, a Taipei City, Taiwan-based pharmaceutical company and CDMO of drug products, has completed its acquisition of Emergent’s sterile manufacturing facility in Baltimore-Camden, Maryland. 

The newly acquired 87,000-square-foot facility provides drug product manufacturing services for sterile injectables and clinical and commercial non-viral aseptic fill–finish services of vials and pre-filled syringes on four fill lines, lyophilization, formulation development, and support services. 

In May 2024, Emergent announced the next phase of a new operational plan that consolidates operations, closes several manufacturing facilities, and restructures its workforce. As part of its operational changes, Emergent will shut down both its Baltimore-Bayview, drug-substance manufacturing facility and Rockville, Maryland, drug-product facility. Emergent will concentrate operations at sites in Winnipeg, Canada, and Lansing, Michigan, while the company explores strategic alternatives for its other sites throughout the year (2024).   

Source: Bora Pharmaceuticals